TL;DR
This paper provides a quantitative risk-benefit analysis of COVID-19 vaccination for adolescents (12-17 years old) in England. It concludes that the benefits of vaccination, particularly in preventing hospitalizations and long COVID, significantly outweigh the risks, even at lower infection rates.
What Problem Does This Paper Address?
The paper addresses the ongoing debate and policy decisions surrounding the vaccination of adolescents against SARS-CoV-2. Specifically, it aims to provide a data-driven assessment to inform public health recommendations, contrasting with the UK's Joint Committee on Vaccination and Immunisation's initial cautious stance. The authors highlight the need for a clear understanding of the potential risks (like myocarditis) versus the benefits (preventing severe illness, hospitalization, and long COVID) in this age group, especially considering varying infection rates and the emergence of new variants.
Methods
The authors employed a risk-benefit analysis methodology, drawing inspiration from the US Centers for Disease Control (CDC) approach. They utilized historical data on SARS-CoV-2 cases, hospital admissions, Intensive Care Unit (ICU) admissions, and deaths in English children aged 12-17. This data was then combined with estimates for:
- Incidence of long COVID: Using a range of 2%, 4%, and 14% based on existing studies.
- Vaccine efficacy: Considering effectiveness in reducing severe outcomes and infections.
- Vaccine-induced myocarditis/pericarditis: Incorporating rare but known risks, particularly for boys after the second dose.
They modeled outcomes over a 16-week period under both high (1000/100,000/week) and low (50/100,000/week) future case incidence scenarios. A key aspect of their method was to focus solely on direct benefits to children, excluding broader societal impacts like reduced transmission or educational disruption, to align with the JCVI's remit.
Datasets
The study utilized linked electronic health records from multiple sources in England, accessed through the British Heart Foundation Data Science Centre. These sources included:
- Public Health England's Second Generation Surveillance System (national testing laboratory).
- Primary care consultations in General Practice Extraction Service Data for Pandemic Planning and Research.
- Hospitalisations (including ICU admissions and ventilation) from Hospital Episode Statistics and the COVID-19 Hospitalisations in England Surveillance System.
- Deaths from the Office of National Statistics.
Data on vaccine-associated myocarditis/pericarditis and long COVID incidence were drawn from published literature and reports.
Key Insights and Ideas
- Direct benefit outweighs risk: The core finding is that vaccination offers substantial direct benefits to adolescents, significantly reducing hospitalizations and deaths, and preventing a large number of long COVID cases.
- Long COVID is a major consideration: The potential for long COVID, even in otherwise healthy children, is a significant factor that strongly favors vaccination.
- Threshold for benefit: Vaccination provides a net benefit in terms of hospitalizations unless case rates are sustainably very low (below 30/100,000 teenagers/week). This threshold is even lower for girls due to the differential risk of vaccine-associated myocarditis.
- Myocarditis risk is manageable: While vaccine-associated myocarditis is a recognized risk, the analysis assumes a worst-case scenario where all cases require hospitalization, and even then, the benefits of vaccination still outweigh the risks. The paper notes that most cases are mild and recover well.
- Conservative assumptions: The analysis uses conservative estimates for vaccine effectiveness and case ascertainment, suggesting that the true benefits might be even greater.
Key Results
- High Incidence Scenario (1000/100,000/week): Vaccination could avert approximately 4430 hospital admissions and 36 deaths over 16 weeks. It could also prevent 56,000, 16,000, or 8000 cases of long COVID, depending on the incidence rate (14%, 4%, or 2%).
- Low Incidence Scenario (50/100,000/week): Vaccination could avert around 70 hospital admissions and two deaths over 16 weeks, along with 2800, 800, or 400 cases of long COVID.
- Hospitalization Threshold: The risk of hospitalization from vaccination only exceeds the risk from COVID-19 at case incidence rates below 30/100,000/week, a level not seen in English adolescents in 2021.
- Myocarditis Cost: The analysis accounts for 160 cases of vaccine-associated myocarditis/pericarditis over 16 weeks, which is considered a manageable cost against the averted outcomes.
Limitations and Future Work
- Exclusion of secondary benefits: The analysis explicitly excludes broader benefits like reduced community transmission and educational disruption, which would further strengthen the case for vaccination.
- Incidental positive tests: The study acknowledges that some hospital admissions with a positive COVID-19 test might be incidental findings, a factor that would require more complex analysis.
- Sub-analysis by health conditions: The authors could not perform sub-analyses based on pre-existing health conditions due to data limitations, though they note that many severe COVID-19 cases occur in children without such conditions.
- Single vs. Double Doses: The analysis focuses on two doses, acknowledging uncertainty around the durability and protection of a single dose.
- Constant Case Rates: The 16-week period assumes constant case rates, which is an artificial simplification.
- Logistical factors: The paper does not consider the logistical challenges of expanding vaccination programs to adolescents.
Future work could involve incorporating secondary benefits, addressing incidental positive tests, and conducting more detailed sub-analyses. The authors also invite the JCVI to share their data and calculations for transparency and further scrutiny.
Summary updated